MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-18-2022
CureVac N.V. Total Liabilities 2011-2026 | CVAC
Annual Total Liabilities CureVac N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 470 M | 800 M | 173 M | 93.6 M | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 800 M | 93.6 M | 384 M |
Quarterly Total Liabilities CureVac N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 303 M | 352 M | 470 M | 968 M | - | - | 800 M | - | - | - | 173 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 968 M | 173 M | 511 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Annovis Bio
ANVS
|
18 M | $ 2.52 | 1.2 % | $ 22.7 M |  USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.56 | 3.79 % | $ 8.57 B |  Australia |
 |
Actinium Pharmaceuticals
ATNM
|
44.1 M | $ 1.21 | 0.74 % | $ 36.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
355 M | $ 1.62 | 7.28 % | $ 413 M |  Britain |
 |
Axsome Therapeutics
AXSM
|
602 M | $ 162.88 | 0.34 % | $ 8.1 B | USA |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.58 | 2.38 % | $ 16.2 M | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
BridgeBio Pharma
BBIO
|
3.01 B | $ 64.71 | -0.99 % | $ 12.4 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
164 M | $ 5.32 | 2.31 % | $ 310 M | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Atara Biotherapeutics
ATRA
|
206 M | $ 7.11 | 37.52 % | $ 53.2 M | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Beam Therapeutics
BEAM
|
243 M | $ 26.95 | 1.53 % | $ 2.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.76 B | $ 9.66 | -2.62 % | $ 625 M | USA |
 |
Biogen
BIIB
|
11.2 B | $ 184.68 | -0.1 % | $ 27.1 B | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
BioVie
BIVI
|
2.55 M | $ 1.34 | -1.47 % | $ 1.98 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioLineRx Ltd.
BLRX
|
25.4 M | $ 2.65 | - | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
1.51 B | $ 60.17 | -1.55 % | $ 11.5 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
71.5 B | $ 60.1 | -0.32 % | $ 122 B | USA |
 |
Benitec Biopharma
BNTC
|
2.3 M | $ 12.76 | 12.52 % | $ 525 M | USA |
 |
BioNTech SE
BNTX
|
3.12 B | $ 100.99 | -0.51 % | $ 27.2 B | Germany |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
ADC Therapeutics SA
ADCT
|
440 M | $ 4.07 | -0.73 % | $ 105 M |  Schweiz |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
BioXcel Therapeutics
BTAI
|
131 M | $ 1.72 | 16.22 % | $ 4.36 M | USA |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 8.05 | 3.67 % | $ 1.31 B | Britain |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
BeyondSpring
BYSI
|
48.6 M | $ 1.45 | - | $ 58.5 M | USA |
 |
Cabaletta Bio
CABA
|
17.5 M | $ 3.18 | 0.42 % | $ 3.71 M | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.93 | -13.63 % | $ 8.55 B | Israel |
 |
Capricor Therapeutics
CAPR
|
36.1 M | $ 29.47 | 5.61 % | $ 789 M | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Catalyst Biosciences
CBIO
|
38.1 M | $ 11.83 | -2.03 % | $ 779 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
C4 Therapeutics
CCCC
|
102 M | $ 3.62 | 18.91 % | $ 300 M | USA |
 |
Codexis
CDXS
|
82.1 M | $ 1.23 | -0.41 % | $ 90.3 M | USA |
 |
Cerus Corporation
CERS
|
157 M | $ 1.86 | -3.89 % | $ 355 M | USA |